Results 131 to 140 of about 334,171 (270)

Two Different Subunits Associate to Create Isoform-Specific Platelet-derived Growth Factor Receptors

open access: hybrid, 1989
Ronald A. Seifert   +6 more
openalex   +1 more source

Macrophage HM13/SPP Enhances Foamy Macrophage Formation and Atherogenesis

open access: yesAdvanced Science, EarlyView.
Previous research suggests that AIP may prevent atherogenic foamy macrophage formation. This study reveals that AIP, via its chaperone interaction with AHR, inhibits p38‐c‐JUN‐mediated transactivation of HM13, which encodes the ERAD protease HM13/SPP. HM13/SPP promotes foamy macrophage formation in addition to atherogenesis and plaque foamy macrophage ...
Yu Cao   +15 more
wiley   +1 more source

A Soluble Platelet-Derived Growth Factor Receptor-β Originates via Pre-mRNA Splicing in the Healthy Brain and Is Upregulated during Hypoxia and Aging. [PDF]

open access: yesBiomolecules, 2023
Payne LB   +10 more
europepmc   +1 more source

Tumoroid Model Reveals Synergistic Impairment of Metabolism by Iron Chelators and Temozolomide in Chemo‐Resistant Patient‐derived Glioblastoma Cells

open access: yesAdvanced Science, EarlyView.
This study investigates the metabolic vulnerabilities of glioblastoma (GBM), an aggressive brain tumor. Research demonstrates that iron chelation therapy, in combination with standard chemotherapy, significantly enhances the efficacy of treatment against resistant GBM cells in a 3D tumoroid model.
Meitham Amereh   +8 more
wiley   +1 more source

Case report: a case of lung squamous cell carcinoma with a novel FGFR3-IER5L fusion mutation responding to anlotinib

open access: yesFrontiers in Oncology
Lung squamous cell carcinoma (LUSC) is the second most common pathological type of non-small cell lung cancer (NSCLC). However, compared with lung adenocarcinoma (LUAD), the incidence of driver gene mutations in LUSC is relatively lower and treatment ...
Xiaoting Chen   +7 more
doaj   +1 more source

New natural compound inhibitors of PDGFRA (platelet-derived growth factor receptor α) based on computational study for high-grade glioma therapy. [PDF]

open access: yesFront Neurosci, 2022
Yang W   +18 more
europepmc   +1 more source

YC‐4‐3, a Novel Glycogen Synthase Kinase 3β Inhibitor, Alleviates the Endoplasmic Reticulum Stress of Macrophages in Primary Immune Thrombocytopenia

open access: yesAdvanced Science, EarlyView.
A patented GSK‐3β inhibitor (GSK‐3βi), new benzothiazepinone compounds (BTZs), YC‐4‐3, can modulate the inflammatory status of macrophages in primary immune thrombocytopenia (ITP), and improve the thrombocytopenia in murine ITP models by directly interacting with endoplasmic reticulum (ER) stress response.
Pengcheng Xu   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy